Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065074 | 0.93 | GCK (0.41) | GCK | |
| SCHEMBL4288751 | 0.93 | GCK (0.41) | GCK | |
| SCHEMBL4299272 | 0.93 | GCK (0.41) | GCK | |
| SCHEMBL1059990 | 0.92 | GCK (0.40) | GCK | |
| SCHEMBL1061035 | 0.92 | GCK (0.40) | GCK | |
| SCHEMBL1064911 | 0.92 | GCK (0.40) | GCK | |
| SCHEMBL4296982 | 0.92 | GCK (0.40) | GCK | |
| SCHEMBL4289093 | 0.91 | GCK (0.41) | GCK | |
| SCHEMBL1061808 | 0.91 | GCK (0.40) | GCK | |
| SCHEMBL1058599 | 0.91 | GCK (0.40) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | claimed |
| US-20060194814-A1 | Benzamide compounds | GEORGETOWN UNIVERSITY | 2006-08-31 | — | — | US | claimed |
| US-20060194815-A1 | Methods and compositions for modulating serum cortisol levels | GEORGETOWN UNIVERSITY | 2006-08-31 | — | — | US | claimed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090286876-A1 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090197891-A1 | Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease | SAMARITAN PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20060167108-A1 | Neuroprotective benzoate and benzamide compounds | GEORGETOWN UNIVERSITY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194815-A1 | Methods and compositions for modulating serum cortisol levels | CRH, SERPINA6, BCHE | GCK 2121/4885 |
| US-20060194814-A1 | Benzamide compounds | PIGS, BCAT2, GBA1 | GCK 3372/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | GCK 1/4885 |
| US-20090286876-A1 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | ABAT, GABRB2, GABRB1 | GCK 1650/4885 |
| US-20060167108-A1 | Neuroprotective benzoate and benzamide compounds | ABAT, GABRB2, GABRB1 | GCK 1650/4885 |
| US-20090197891-A1 | Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease | APP, PSEN1, PSEN2 | GCK 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.